Latest news

Thumbnail image for BMS’ Opdivo cuts risk of melanoma recurrence

BMS’ Opdivo cuts risk of melanoma recurrence

Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning.

5th June 2018

Thumbnail image for MSD’s Keytruda takes lead in squamous NSCLC trials

MSD’s Keytruda takes lead in squamous NSCLC trials

MSD’s Keytruda has shown a greater benefit than Roche’s Tecentriq in separate (and incomparable) clinical trials exploring the effectiveness of the anti-PD-1 therapies in treatment-naiive patients with squamous non-small cell lung cancer.

4th June 2018

Thumbnail image for US approves Lilly/Incyte’s Olumiant

US approves Lilly/Incyte’s Olumiant

As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).

4th June 2018

Thumbnail image for Novartis’ Aimovig leads CHMP recommendations

Novartis’ Aimovig leads CHMP recommendations

The European Medicines Agency’s Committee for Medicinal Products for Human Use has endorsed nine medicines for approval at its May meeting, including Novartis’ Aimovig, the first human monoclonal antibody for migraine prevention.

4th June 2018

Thumbnail image for Priority review for Astellas’ AML drug

Priority review for Astellas’ AML drug

Astellas Pharma’s gilteritinib is under priority review in the US as potential treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.

30th May 2018

Previous  --   7 8 9 10 11 12 13 14 15 16   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download